Total Funding
2
11
Total FundingPost-IPO Equity raised
Growth Score
1 pts
Heat Score
-2 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
1066478
Cerulean Pharma develops nanotechnology-based therapeutics for treating oncology, cardiovascular, autoimmune and inflammatory diseases.
Acquired by 
Daré Bioscience
Oliver Fetzer: President and Chief Executive OfficerPast Role: Cubist Pharmaceuticals, Senior Vice President, Corporate Development and Research and Development
Rob Paull: DirectorPast Role: Outsized Ventures, Advisor
About the Company
Cerulean Pharma Inc. is a privately-held biopharmaceutical company focused on the development of novel nanotechnology-based therapeutics in the areas of oncology, cardiovascular, autoimmune and inflammatory diseases.
The Company has assembled a world-class management team, board of directors and scientific advisory board that collectively have
a significant track record of business building, product development and scientific breakthroughs from companies and institutions such as Cubist, GlaxoSmithKline, Merck, Millennium Pharmaceuticals, Inc., Pfizer, Wyeth, the Massachusetts Institute of Technology, Harvard Medical School, MD Anderson, Fox Chase Cancer Center and the Arizona Health Center.
